[go: up one dir, main page]

CL2018002074A1 - Composiciones y métodos para tratar infecciones. - Google Patents

Composiciones y métodos para tratar infecciones.

Info

Publication number
CL2018002074A1
CL2018002074A1 CL2018002074A CL2018002074A CL2018002074A1 CL 2018002074 A1 CL2018002074 A1 CL 2018002074A1 CL 2018002074 A CL2018002074 A CL 2018002074A CL 2018002074 A CL2018002074 A CL 2018002074A CL 2018002074 A1 CL2018002074 A1 CL 2018002074A1
Authority
CL
Chile
Prior art keywords
methods
compositions
treat infections
infections
inhibitors
Prior art date
Application number
CL2018002074A
Other languages
English (en)
Inventor
Stephen Thomas
Allen T Hopper
Mathew Welsch
Original Assignee
Vyera Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vyera Pharmaceuticals Llc filed Critical Vyera Pharmaceuticals Llc
Publication of CL2018002074A1 publication Critical patent/CL2018002074A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

LA INVENCIÓN SE REFIERE A INHIBIDORES DE DIHIDROFOLATO REDUCTASA Y A PREPARACIONES FARMACÉUTICAS DE LOS MISMOS. LA INVENCIÓN SE REFIERE ADEMÁS A MÉTODOS DE TRATAMIENTO DE INFECCIONES PARASÍTICAS, TALES COMO INFECCIONES POR T. GONDII, T. CRUZI, P. FALCIPARUM, T. BRUCEI O L. MAJOR, USANDO LOS NUEVOS INHIBIDORES DE LA INVENCIÓN.
CL2018002074A 2016-02-05 2018-08-02 Composiciones y métodos para tratar infecciones. CL2018002074A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662291900P 2016-02-05 2016-02-05
US201662375712P 2016-08-16 2016-08-16

Publications (1)

Publication Number Publication Date
CL2018002074A1 true CL2018002074A1 (es) 2019-02-01

Family

ID=59500993

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002074A CL2018002074A1 (es) 2016-02-05 2018-08-02 Composiciones y métodos para tratar infecciones.

Country Status (17)

Country Link
US (2) US10774073B2 (es)
EP (1) EP3411367A4 (es)
JP (1) JP6949055B2 (es)
KR (1) KR20180119590A (es)
CN (1) CN109071486A (es)
AU (2) AU2017213824B9 (es)
BR (1) BR112018015924A2 (es)
CA (1) CA3013760A1 (es)
CL (1) CL2018002074A1 (es)
CU (1) CU20180083A7 (es)
EA (1) EA201891766A1 (es)
IL (2) IL260952B (es)
MX (1) MX2018009504A (es)
PH (1) PH12018501646A1 (es)
SG (2) SG10202007239QA (es)
TW (1) TW201731836A (es)
WO (1) WO2017136556A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136556A1 (en) 2016-02-05 2017-08-10 Turing Pharmaceuticals Llc Compositions and methods for treating infections
US20200270233A1 (en) * 2017-08-07 2020-08-27 Vyera Pharmaceuticais LLC Dhfr inhibitors, compositions, and methods related thereto
EP3795684A4 (en) * 2018-04-26 2022-01-05 Guangzhou Cas Lamvac Biotech Co., Ltd. MITIGATION SYSTEM AND ASSOCIATED USE
JP2023539463A (ja) 2020-08-17 2023-09-14 アリゴス セラピューティクス インコーポレイテッド Ｐｄ－ｌ１を標的とするための方法及び組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4532240A (en) 1982-09-09 1985-07-30 Warner-Lambert Company Diaminopyrimidines
JPS5973573A (ja) * 1982-09-09 1984-04-25 ワ−ナ−−ランバ−ト・コンパニ− ジアミノピリミジン化合物
CA1244028A (en) 1983-04-14 1988-11-01 Hans Maag Pyrimidine derivatives
ZA842595B (en) * 1983-04-14 1985-11-27 Hoffmann La Roche Pyrimidine derivatives
WO2000009131A1 (en) * 1998-08-13 2000-02-24 Warner-Lambert Company Diaminopyrimidines and combination therapies effective for treatment of p-glycoprotein positive cancers
US20040006042A1 (en) * 1998-08-13 2004-01-08 Berry David Allen Diaminopyrimidines and combination therapies effective for treatment of P-glycoprotein positive cancers
AU2004263373A1 (en) * 2003-08-07 2005-02-17 Pharmacia & Upjohn Company Llc Anthelmintic and insecticide pyrimidine derivatives
WO2017136556A1 (en) * 2016-02-05 2017-08-10 Turing Pharmaceuticals Llc Compositions and methods for treating infections
US20200270233A1 (en) 2017-08-07 2020-08-27 Vyera Pharmaceuticais LLC Dhfr inhibitors, compositions, and methods related thereto

Also Published As

Publication number Publication date
US20200407345A1 (en) 2020-12-31
US20190077794A1 (en) 2019-03-14
CN109071486A (zh) 2018-12-21
JP6949055B2 (ja) 2021-10-13
WO2017136556A1 (en) 2017-08-10
PH12018501646A1 (en) 2019-05-27
CU20180083A7 (es) 2019-03-04
EA201891766A1 (ru) 2019-02-28
SG10202007239QA (en) 2020-09-29
KR20180119590A (ko) 2018-11-02
IL260952B (en) 2022-04-01
TW201731836A (zh) 2017-09-16
US10774073B2 (en) 2020-09-15
BR112018015924A2 (pt) 2018-12-26
SG11201806620TA (en) 2018-09-27
EP3411367A1 (en) 2018-12-12
AU2022200967A1 (en) 2022-03-03
AU2017213824A1 (en) 2018-09-06
CA3013760A1 (en) 2017-08-10
IL291266A (en) 2022-05-01
US11530198B2 (en) 2022-12-20
AU2017213824B2 (en) 2021-11-18
AU2017213824B9 (en) 2021-11-25
JP2019504889A (ja) 2019-02-21
EP3411367A4 (en) 2019-07-10
MX2018009504A (es) 2019-05-06

Similar Documents

Publication Publication Date Title
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
MX2018006148A (es) Inhibidores de cxcr2.
MX2018016273A (es) Compuestos heterociclicos como inmunomoduladores.
MX2017002670A (es) Inhibidores de glucosidasa.
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX389627B (es) Inhibidores de la magl.
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201790571A1 (ru) Пирролопиримидины для применения при инфекции, вызванной вирусом гриппа
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
MX378108B (es) Anticuerpos anti-met y composiciones.
DK3386991T3 (da) Polycykliske forbindelser som inhibitorer af bruton's tyrosinkinase
IL252900B (en) Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
UY35274A (es) Compuestos y métodos para tratar infecciones bacterianas
EA201790570A1 (ru) Модуляторы р2х7
IL268728A (en) Formulations of cannabinoids for the treatment of acne
EP3731832A4 (en) CANNABINOID DOSAGE FORM
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
CO2017001389A2 (es) Compuestos de azetidiniloxifenilpirrolidina
CL2018002074A1 (es) Composiciones y métodos para tratar infecciones.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
CL2017000178A1 (es) Compuestos para usar en el tratamiento antihelmíntico
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба